Drugs / AVX901
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01526473 | Feb 2012 → Mar 2016 | HER2 positive breast carcinoma | H. Kim Lyerly | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVX901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01526473 ↗ |
| Modality | Vaccine | “This clinical trial will use an investigational cancer vaccine called HER2 VRP or AVX901.” NCT01526473 ↗ |
| Route | Intramuscular | “AVX901 at 4 x 108 IU intramuscularly” NCT01526473 ↗ |